CDX2 and cholangiocarcinoma: Although there is no characteristic panel of antibodies that are pathognomonic for cholangiocarcinoma, tumors of biliary epithelial origin tend to express CK7 and sometimes CK20 although they lack CDX2 expression [7, 8].